Elissa Kalver was diagnosed with HER2-positive metastatic breast cancer at 34. Since then, she has founded a nonprofit and ...
In an interview with Targeted Oncology, Gerrina Ruiter, MD, PhD, Netherlands Cancer Institute and study investigator, ...
Trastuzumab deruxtecan (T-DXd) significantly improves IDFS over trastuzumab emtansine (T-DM1) in high-risk HER2-positive ...
October is Breast Cancer Awareness Month, and CURE is here to address some of the most common questions patients have after a ...
This marks the first and only antibody drug conjugate in India with a tumour-agnostic indication, representing a significant ...
For patients with high-risk HER2-positive early breast cancer who have undergone neoadjuvant therapy, treatment with Enhertu ...
ENHERTU Followed by THP sBLA Accepted in the U.S. for Patients with High-Risk HER2+ Early Breast Cancer Prior to Surgery ...
9don MSN
What Oncologists Want You to Know About the Types of Breast Cancer—and How It Could Save Your Life
No two cases are alike, but there are distinct types of breast cancer. Here, oncologists share what you need to know about ...
Daiichi Sankyo submits sNDA to Japan’s MHLW for Enhertu plus pertuzumab to treat patients with HER2 positive unresectable or recurrent breast cancer: Tokyo Wednesday, October 8, ...
Bangalore: AstraZeneca Pharma India Limited has received approval from the Central Drugs Standard Control Organisation (CDSCO ...
Elissa Kalver was 34 when she found a lump in her breast. She had no family history of cancer and had just welcomed her first child. She assumed the lump was a cyst. But when she went to get it ...
LAUSANNE, Switzerland & SANTIAGO DE COMPOSTELA, Spain, September 30, 2025--Debiopharm ( a privately-owned, Swiss-based, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback